Effect of Body Mass Index on Serum CA125 Level in Females with PCOS

Authors

  • Hanan Abdulmaged Hasan High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University, Baghdad, Iraq
  • Mohammed Oda Selman High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University, Baghdad, Iraq
  • Mufeda Ali Jwad High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University, Baghdad, Iraq

DOI:

https://doi.org/10.28969/IJEIR.v10.i1.r7

Keywords:

CA125, PCOS, ELISA, LH, FSH, BMI

Abstract

CA125 is a glycoprotein mucins (MUC16) tumor marker, used in screening, ovarian and endometrial malignancies and in monitoring therapy, early recurrences, and prognosis of these cancers. Hormonal induction for ovulation can elevate the risk of ovarian cancers so CA125 may be used for screening in PCOS as an unsafe group and the way of treatment may need to be changed in these patients. Polycystic Ovarian Syndrome (PCOS) is one of the most common hormonal disturbed diseases that can affect females in reproductive life. It has both metabolic and fertility impacts that can be seen in the reproductive period and post-menopausal life. To study the correlation between PCOS and CA125 level in relation to body weight in non-cancerous patients. 60 women were selected with age 18-42-year-old forty of them were diagnosed with PCOS according to Rotterdam criteria. They were divided into two groups according to BMI G1 was more than 25 kg/m2 (overweight and obese) G2 was less than 25 kg/m2 (normal) and the G3 was 20 healthy non-PCOS BMI less than 25 kg/m2. Blood samples were taken in the early follicular phase for assessing luteinizing hormone (LH), follicular stimulating hormone (FSH) and, free testosterone (FT) hormone. Other blood samples were taken at the late follicular phase to measure CA125 levels using Enzyme-Linked Immune Sorbent Assay (ELISA). PCOS G2 were significantly higher in the concentration of CA125 than PCOS G1 (p< 0.05), but there was no significant difference in CA125 level in groups when there is no significant difference in body mass index (BMI) between PCOS G1 and G2. P>0.05. The negative relation between CA125 concentration and weight. The tumor marker CA125 efficacy is decreased in obese women. Furthermore, PCOS not causes an increase in CA125 in the non-cancerous patient.

Author Biographies

Hanan Abdulmaged Hasan, High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University, Baghdad, Iraq

 

Dr. Hanan Abdulmaged Hasan     She is a General Practioner with a special interest in Dermatology. She graduated from The College of Medicine, Baghdad University in Iraq in 1987. She worked in Baghdad hospitals and medical centers then she retired for medical reasons. She has obtained a Master's degree in Applied Embryology in 2020.

Mohammed Oda Selman, High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University, Baghdad, Iraq

 

Dr. Mohammed Oda Selman     He is a professor of Applied Embryology in the High Institute for Infertility Diagnosis and ART, Al-Nahrain University. He has more than 70 published articles both local and international. He supervised many M.Sc. and Ph.D. students.

Mufeda Ali Jwad, High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University, Baghdad, Iraq

 

Dr. Mufeda Ali Jwad     She received her MBChB. From the College of Medicine at the University of Baghdad in 1996. Her M.Sc. in Applied Embryology and her Ph.D. in Infertility and Clinical Reproduction were from the High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University in 2007 and 2018 respectively. She worked as a rotator in the Baghdad health department from 1996-1999. She worked in Gyn. & Obs. in Alsamawa general hospital and Babylon hospital from 2000-2003. She worked at the Babylon University, College of Medicine, anatomy and embryology department from 2003-2004. She has been working as a specialist physician and a consultant clinic at the High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University from 2008-2015. Currently, she is an assistant professor and specialist in infertility and clinical reproduction. She is the head of the clinical reproductive physiology department from 2019 till now. She has more than 25 published articles in national and international journals.

References

Park C-H, Chun S. Association between serum gonadotropin level and insulin resistance-related parameters in Korean women with polycystic ovary syndrome. Obstet Gynecol Sci. 2016;59(6):498. [Online Article Link]

Kabel A. Polycystic Ovarian Syndrome : Insights into Pathogenesis, Diagnosis, Pathog Pcos. 2016;1(1):1–5. [Online Article Link]

Selman MO, Al-hassani WR, Al-wasiti E, Mahdi KT, Suhail AM. Role of IGF 1, VEGF, Vit. D3 and Vit. B12 in high AMH level in Iraqi Infertile women as criteria to prepare them for IVF. 2019;7(7):237–40. [Online Article Link]

Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of the different pcos phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. Indian J Endocrinol Metab. 2019;23(3):326. [Online Article Link]

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Vol. 81, Fertility and Sterility. 2004. p. 19–25. [Online Article Link]

Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and Pcos Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome - Part 1, Endocrine Practice. 2015:21(11), 1291–1300. [Online Article Link]

Filippou P, Homburg R. Is foetal hyperexposure to androgens a cause of PCOS ? Human Reproduction Update. 2017;23(4):421–32. [Online Article Link]

Tokmak A, Kokanali MK, Guzel AI, Kara A, Topcu HO, Cavkaytar S. Polycystic ovary syndrome and risk of endometrial cancer: A mini-review, Asian Pacific Journal of Cancer Prevention, 2014;15(17):7011–7014. [Online Article Link]

Singh AP, Senapati S, Ponnusamy, MP, Jain M, Lele SM, Davis JS, Remmenga S, Batra, SK. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 2008;9(11):1076–85. [Online Article Link]

Zhu H, Zhu X, Zheng L, Hu X, Sun, L, Zhu X. The role of the androgen receptor in ovarian cancer carcinogenesis and its clinicalimplications. Oncotarget, 2017;8:29395-29405. [Online Article Link]

Balen A. Polycystic ovary syndrome and cancer, Human Reproduction Update, 2001;7(6):522–525. [Online Article Link]

Momenimovahed Z, Taheri S, Tiznobaik A, Salehiniya H. Do the Fertility Drugs Increase the Risk of Cancer? A Review Study. Front Endocrinol (Lausanne). 2019 May 24;10:313. [Online Article Link]

Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: Revisiting old hypotheses Jean. Molecular and Cellular Endocrinology, 2006 Mar 9;247(1-2):4-21. [Online Article Link]

Gardener DK, Ariel W, Haowles CM, Shoham Z (eds.). Textbook of Assisted Reproductive Techniques. 5th edition. CRC Press; 2018. [Online Article Link]

Schneider J, Martín-Gutiérrez S, Tresguerres JA, García-Velasco JA. Circulating estradiol defines the tumor phenotype in menopausal breast cancer patients. Maturitas. 2009;64(1):43–5. [Online Article Link]

Mujawar SA, Kurude VN, Gaikwad HA, Patil VW. Utility of ovarian tumour marker cancer antigen-125 and endocrine hormonal status in polycystic ovary syndrome. J Clin Diagnostic Res. 2018 Oct 1;12(10):BC01–3. [Online Article Link]

Allahbadia GN, Merchant R. Polycystic ovary syndrome and impact on health. Middle East Fertility Society Journal. 2011;16(1):19–37. [Online Article Link]

Gadducci A, Gargini A, Palla E, Fanucchi A, Genazzani AR. Polycystic ovary syndrome and gynecological cancers: Is there a link? Gynecological Endocrinology. 2005;20(4):200–8. [Online Article Link]

Alsadi B. Polycystic Ovary Syndrome, Pathophysiology, and Reproductive Health Implications, In Pathophysiology, Gaze DC (ed.), Intech, 2018. [Online Article Link]

Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, et al. MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13:129. [Online Article Link]

Sharma S. Tumor markers in clinical practice: General principles and guidelnes. Indian J Med Paediatr Oncol. 2009;30(1):1-8. [Online Article Link]

Chen F, Shen J, Wang J, Cai P, Huang Y. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: Diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res. 2018 May 22;10:1313–8. [Online Article Link]

Aithal A, Rauth S, Kshirsagar P, Shah A, Lakshmanan I, Junker WM, et al. MUC16 as a novel target for cancer therapy. Expert Opinion on Therapeutic Targets. Taylor and Francis Ltd; 2018;22:675–86 .[Online Article Link]

Lujan ME, Chizen DR, Pierson RA. Diagnostic Criteria for Polycystic Ovary Syndrome : Pitfalls and Controversies. Journal of Obstetrics and Gynaecology Canada; 2008;30(8):671–679. [Online Article Link]

De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update Reproductive Biology and Endocrinology. BioMed Central Ltd. 2016;14:38. [Online Article Link]

Hsu MI. Clinical characteristics in Taiwanese women with polycystic ovary syndrome. Clinical and experimental reproductive medicine. 2015:42(3):86-93. [Online Article Link]

Rzaij ZF, AL-Ani NKH. Evaluation of Cancer Antigens (CA125&CA153-) in some Iraqi women with polycystic ovarian syndrome. Iraqi J Embryos Infertil. Res. 2013;3(6):11–4. [Online Article Link]

Kim JH, Park BR, Yang WJ. Dilution effect of serum CA125 a19-9 over a cutoff value, according to obesity, Int J Biol Markers. 2015 Feb 24;30(1):e122-6. [Online Article Link]

Johnson CC, Kessel B, Riley TL, Ragard LR, Williams CR, Xu JL, Buys SS, Prostate, Lung, Colorectal and Ovarian Cancer Project Team. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecologic-oncology. 2008:110(3),383–9. [Online Article Link]

Published

2020-12-14

How to Cite

1.
Hasan HA, Selman MO, Jwad MA. Effect of Body Mass Index on Serum CA125 Level in Females with PCOS. IJEIR [Internet]. 2020 Dec. 14 [cited 2024 Mar. 28];10(1):101-18. Available from: https://ijeir.net/index.php/ijeir/article/view/v10p07-ijeir-2020

Issue

Section

Research Articles